AC
TARA icon

AXQ Capital’s Protara Therapeutics TARA Stock Holding History

AXQ Capital’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.7K Buy
13,002
+2,187
+20% +$12.9K 0.01% 911
2025
Q4 		$57.6K Buy
+10,815
New +$60.1K 0.01% 685

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

AXQ Capital's TARA Position: Q1 2026 in Review

AXQ Capital increased its Protara Therapeutics (TARA) stake by 20% in Q1 2026, buying an estimated $12.9K and bringing the position to 13,002 shares worth $67.7K. The position accounts for 0.01% of the portfolio, ranked #911.

AXQ Capital first reported a position in TARA in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • AXQ Capital held 13,002 shares of Protara Therapeutics worth $67.7K as of Q1 2026.
  • AXQ Capital bought 2,187 Protara Therapeutics shares in Q1 2026, an estimated $12.9K.
  • Protara Therapeutics made up 0.01% of AXQ Capital's portfolio in Q1 2026, its #911 holding.
  • AXQ Capital first reported a position in Protara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.